Table 2.

Clinical trials of CAR-Ts for MM with published results

TargetInstitutionCAR constructConditioning chemotherapyResponseReference
CD138Chinese People's Liberation Army General HospitalLentivirus; CD28 costimulatory molecule; murine scFvVaried, all patients received some type of chemotherapy shortly before cell infusion5 patients treated; best responses: 4 SD, 1 PD36
CD19University of PennsylvaniaLentivirus 4-1BB costimulatory molecule; murine scFvMelphalan 140-200 mg/m2 prior to ASCT10 patients treated; median PFS 185 d (range, 42-479 d)10, 35
Immunoglobulin κ light chainBaylor College of Medicineγ- retrovirus; CD28 costimulatory molecule; murine scFvSalvage chemotherapy by referring physician (3 patients) or 12.5 mg/kg cyclophosphamide 4 days prior to CAR-T infusion (4 patients)7 patients treated: 4 SD, 3 no response21
BCMANational Cancer Instituteγ-retrovirus; CD28 costimulatory molecule; murine scFv3 doses of 300 mg/m2 cyclophosphamide and 3 doses of 30 mg/m2 fludarabine12 patients treated; best responses: 1 sCR; 2 VGPR; 1 PR; 8 SD9
BCMAMulticenter; Bluebird BioLentivirus; 4-1BB costimulatory molecule; murine scFv3 doses of 300 mg/m2 cyclophosphamide and 3 doses of 30 mg/m2 fludarabineAmong 18 patients with at least 2 mo follow-up, currently, best responses are 4 CR, 7 VGPR, 5 PR, 2 SD102
BCMAUniversity of PennsylvaniaLentivirus; 4-1BB costimulatory molecule; human scFvNone6 patients treated; 1 sCR; 1 VGPR; 4 with minimal or no response37
BCMAThe Second Affiliated Hospital of Xi’an Jiaotong UniversityNot publishedNot publishedAmong 19 patients there was a 100% response rate with 18 patients obtaining sCR or VGPR103